In March 2023, the TGA introduced new label advisory statements for Valerian (Valeriana officininalis, Valerian dry, Valerian powder), Greater Celandine (Chelidonium majus), or Chaparral (Larrea tridentata), following a decision announced in December 2022.

The 12 month transition period for existing medicines that contain these ingredients is coming to an end. All existing products with these ingredients that are released for supply from 1 March 2024 must include the label advisory.

Please read this tech alert for details.